Background Patients with severe Inflammatory Bowel Disease (IBD), are prescribed anti-TNF-a agents, if clinical need necessitates, whose immunosuppressive action can potentially reactivate latent tuberculosis infections (LTBI). Meticulous pre anti-TNF-a LTBI screening and management in accordance with the British Thoracic Society's (BTS) guidelines is imperative for patient safety and public health. Objective A retrospective clinical audit was performed to evaluate the performance of University Hospital Southampton's gastrointestinal department in screening for LTBI in patients with IBD. The performance of LTBI screening was compared to the BTS standards. Method The audit population was obtained using the gastrointestinal department's biologics database. Inclusion criteria included patients who started their first anti-TNF-a agent between 01/01/2006 to 04/11/2016. Exclusion criteria included deceased patients and patients screened by alternative departments/trusts. Extent of LTBI screening was assessed using hospital record systems: EDocs, EQuest, ECamis and Spectra PACS. If evidence of screening was not located, then this was considered as a failure to meet standard. Following statistical analysis, comparisons were made with BTS standards. Results Of the 471 patients audited, 51.2% were females and 48.8% males. 75.2% CD patients and 24.8% UC patients. 231 patients' (49%) LTBI screening was insufficient. 157 patients (33.3%) lacked an adequate TB history and 94 patients (20%) failed to have a chest radiograph (CXR) within 3 months of therapy commencement. Additionally, 85 patients (18.3%) failed to have an IGRA performed. 15 patients (3.2%) were diagnosed with LTBI, whilst 1 case of TB reactivation, occurred once immunosuppressive therapy had commenced. Conclusion The completeness of LTBI screening in the audited group was suboptimal with deficits in TB history performance, CXR, TST and IGRAs. One case of active miliary TB occurred as a result of inadequate screening. In light of this, recommendations to address deficits and ultimately improve screening were proposed.
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QFT-PLUS: DO THE PEPTIDES IN THE TB2 TUBE INDUCE A T SUPPRESSOR RESPONSE IN SOME SUBJECTS?
Introduction The revised QuantiFERON-TB Gold assay (QFTPlus) has an extra tube (TB2), containing peptides thought to stimulate CD8 +T cells; TB7 antigen is no longer included. The test is designed to detect latent tuberculosis infection. Hypothesis Levels of interferon-g in TB2 should always be greater than TB1 Methods QFT-Plus was used routinely in a TB contact clinic June 2016 -January 2017. Interferon-g values were recorded minus the negative control; a significant difference was defined as a two-fold variation. Clinical details were recorded after consent on a standard form, which included age, sex, reason for test, tuberculin response (mm) and HIV status. Results Data was available from 259 subjects; 2 were HIV-positive. Four gave an indeterminate result. The majority (194; 75%) gave a negative test for both tubes. For 65 positive tests with a2 fold difference (all 0.7 IU/mL difference), TB1 TB2 occurred in 4 (6%) and TB2 TB1 occurred in 3 (5%). All 4 TB1 TB2 had no TB2 response: there were 2 contacts (10 and 0.68 IU/ml); one was PPD positive with neck lymphadenopathy (4.23 IU/ml); one was PPD negative with haemoptysis after nasal surgery (1.75 IU/ml). Where TB2 was positive in the 'grey zone' and TB1 negative, one had Crohn's disease (0.24, 0.01 IU/ml) and the other (0.23, 0.01 IU/ml) was a contact of non-pulmonary TB, but in none was there HIV co-infection. Three had TB2 TB1: one with smear-positive lung TB had a TB2=0.6 with a TB1=0.25, but the latter was in an accepted 'grey zone'; two had positive tests for both tubes, of which one was a contact 30 years previously and one had testicular TB. Conclusion These data may indicate a technical failure of the TB2 tube. Alternatively, the absent immune response, associated with active disease, might prove useful in determining who could benefit from preventive treatment.
Abstract P164 Table 1 Highest TB1 or TB2 value (IU/ml) Background The new entrant TB screening programme identified very few persons for Latent TB screening locally. However, following national funding for community LTBI screening, 12 GP practices were identified to undertake IGRA testing in "high risk" registered persons. Aims To evaluate the feasibility and clinical outcomes of the LTBI National Screening Programme Methods From May 2016 until April 2017, persons from countries with high TB incidence (150/100,000 population) and sub-Saharan Africa were identified by the GP practices and offered LTBI screening with IGRA if they had arrived in the UK in the last 5 years and were aged 16-35 years. IGRA Results were forwarded to the TB team at the local hospital. Persons with positive, borderline positive and indeterminate Results were offered appointments for assessment and treatment in the TB Clinic.
Results 360 persons were community-screened for LTBI. Of the 360 persons, 305 (84.7%) had non-reactive IGRA Results and therefore did not require follow up. The remaining 55 (15.3%) had either positive, borderline positive or 2 indeterminate Results and were referred to the local TB team. Of 55 persons referred 2 did not attend any appointments offered and 53 attended 2 of whom were subsequently found to have active TB. The treatment completion rate was 89.2% (see Table 1 ). Despite the inclusion criteria, of the 55 persons offered consultation, 16 had been residing in the UK for more than 5 years and 7 were over the age of 35.
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